Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Auspex Pharmaceuticals
3366 North Torrey Pines Court, Suite 225
La Jolla, CA 92037
Phone: 858-558-2400
www.auspexpharma.com

Auspex Pharmaceuticals is a privately held biopharmaceutical company located in La Jolla, California. The company is a pioneer in the use of deuterium in medicinal chemistry, and is focused on the treatment of hyperkinetic movement disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia. Its lead compound, SD-809, is a novel inhibitor of the vesicular monoamine transporter 2 (VMAT-2). This drug offers the potential for significant advantages over existing therapies including improved safety, reduced drug-drug interactions, and less frequent dosing. Auspex is also exploiting its deuterium chemistry approach to optimize drugs in several additional therapeutic areas. Included in the Auspex portfolio are SD-900, a JAK kinase inhibitor for the treatment of autoimmune diseases, and SD-560, for the treatment of fibrotic diseases, as well as other compounds.

Key Contact
Name
Larry Fritz
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
11/08/12 $25,000,000 Series D CMEA Capital
Panorama Capital
Sloan Biotech Fund
Thomas, McNerney & Partners
undisclosed
01/09/14 $20,000,000 Series E BioMed Ventures
CMEA Capital
Costa Verde Capital
Deerfield Management Company, L.P.
Panorama Capital
Thomas, McNerney & Partners
undisclosed
01/09/14 $15,000,000 Venture Debt Oxford Finance
undisclosed


Featured Reading